Fund Raising Update: Round completed

21-09-2020

In only ten days Leadartis has completed 100% of its fund-raising needs.

We thank you all for your support! We will allow a small overfunding amount, act quickly if you don´t want to miss out!! Visit the following link should you are still interested in participating. https://capitalcell.es/campaign/leadartis/

Regards, Juan J. Perez Villar, Leadartis CEO

Leadartis presenting at the AseBio Investor Day 2020

17-09-2020

Leadartis will be presenting its business proposal at the AseBio Investor Day (https://asebioevents.com/investorday/presenting-companies/) to be held on September 28-October 1st. AseBio Investor Day is the leading event allowing Spanish innovative biotechnology projects to be presented to an audience of leading international investors and pharmaceutical & industrial companies. The event is organized by AseBio, the Spanish Bioindustry Association.

LEADARTIS, THE LEADING IMMUNO-ONCOLOGY COMPANY IN SPAIN, OPENS A €1 MILLION ROUND TOGETHER WITH INVEREADY, SODENA AND CDTI INNVIERTE FOR THE DEVELOPMENT OF ITS FIRST PRODUCT IN ADVANCED CANCERS

11-09-2020

LEADARTIS, a company dedicated to the development of IMMUNO-ONCOLOGICAL medicines based on its own technology (Trimerbody®), opens a financing round of € 1M through the investment platform specialized in biomedicine, Capital Cell. The goal is to continue its research for its first third generation immuno-oncological agent against advanced cancers of the lung, breast and colon. Specifically, the forecast is to finance Phase I studies of its bispecific Trimerbody in patients with advanced or resistant cancers without a therapeutic option.

Trimerbody based therapies for COVID-19: targeting SARS-CoV-2 viral entry mechanism by next-gen trimeric Spikebodies

22-04-2020

The novel coronavirus SARS-CoV-2 has recently emerged as a human pathogen in China, causing fever, severe respiratory illness, and pneumonia a disease recently named coronavirus disease 19 (COVID-19).

LeadArtis to present at the final Chemostart pitching initiative in recognition of its highly innovative R&D activity

31-01-2019
The Chemostart initiative (sponsored by the Chemo company) launched in 2018 as a call for innovative projects focused on adding value to biomedical research. The effort wants to contribute to the discovery of drugs for diseases unmet needs, supporting the best biomedical science. Consequently, the Chemostart initiative (http://www.insudpharma.com/es/chemostart#colaboremos) is meant to promoting the best innovative projects.

Leadartis discloses the project: ATTACK-Cancer immunotherapy by bispecific antibodies that recruit T lymphocytes

11-12-2018

LeadArtis is pleased to announce its participation as coordinator of the ATTACK project (Cancer immunotherapy by bispecific antibodies that recruit T lymphocytes) funded Spanish Ministry of Science, Innovation and Universities (MICINN) under the RETOS 2017 Collaboration program. ATTACK counts with collaborators such as the internationally regarded: Fundación para la Investigación Biomédica del Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid and Centro Nacional de Investigaciones Oncológicas (CNIO).

Medical oncologist Dr. Luis Paz-Ares MD, Ph.D joins Leadartis´ scientific advisory board

10-12-2018

Luis Paz-Ares MD, PhD. Chair of the Medical Oncology Department at the Hospital 12 de Octubre, Associate, Professor at the Universidad Complutense and Head of the Lung Cancer Unit at the CNIO (National Oncology Research Center) in Madrid, Spain recently has joined Leadartis´ scientific advisory board. He graduated in Medicine and completed his PhD at the Universidad Autonoma Madrid (UAM).

Nature Communications: LeadArtis outlines a new bispecific antibody that could hold the key to activate cancer killer T-cells to find and destroy highly prevalent tumors

17-11-2018

LeadArtis and collaborators have published in the highly regarded scientific journal Nature Communications a new tactic to generate a tumor-targeted bispecific antibody to target a particularly relevant immune receptor, 4-1BB, which can activate cancer killer T-cells to erradicate tumors.

Investigadores crean molécula eficaz ante el progreso de células tumorales

15-11-2018

LA VANGUARDIA

Madrid, 15 nov (EFE).- Un grupo de investigadores del Hospital 12 de Octubre de Madrid ha coordinado el diseño de una nueva molécula que reducirá la progresión de células tumorales de una forma más segura y eficaz, que supone un avance en el tratamiento con inmunoterapia que se aplicará a todo tipo de cáncer.

LeadArtis project finalist of the Kaertor and J&J innovation award in recognition of its highly innovative R&D activity

08-11-2018
The Kærtor Foundation together with Janssen (a Johnson & Johnson company) launched in 2018 a call for expressions of interest, focused on adding value to biomedical research from the I2D2 (Incubation Innovation in Drug Discovery) program. The foundation wanted to contribute in this way to the discovery of drugs for diseases without therapeutic solutions, supporting the best biomedical science on the mechanisms of the disease. Consequently, the I2D2 initiative is meant to promoting innovative projects.
Syndicate content

Latest News

SARS-CoV-2 Spike Trimerbody could represent a therapeutic option for COVID-19.
14-10-2021

We are glad to report that in a recently published EMBO Journal...

"Tumor-targeted costimulatory trimerbodies for cancer Immunotherapy”- A brief discussion with Juan Perez Villar, CEO, LEADARTIS.
07-06-2021

...

Diario ABC España y Cadena Cope: Investigadores crean un nuevo anticuerpo antitumoral más eficaz
01-06-2021

El director de la unidad de inmunoterapia del cáncer del Instituto de Investigación del Hospital...